Form 4: Fortress Biotech Executive Vice Chairman Receives 454,153 Restricted Shares

Michael S. Weiss, Executive Vice Chairman of Fortress Biotech, was granted 454,153 restricted shares on January 1, 2025, according to a recent SEC filing.

Summary

• Michael S. Weiss, the Executive Vice Chairman of Fortress Biotech, received 454,153 restricted shares on January 1, 2025.
• These shares were granted under the company's Long-Term Incentive Plan.
• Following this transaction, Mr. Weiss directly owns 1,801,138 shares of Fortress Biotech common stock.

Sentiment

Score: 7

Explanation: The document reflects a standard executive compensation practice, which is generally viewed positively as it aligns management with shareholder interests. There are no negative implications.

Positives

• The grant of restricted shares aligns the executive's interests with the long-term performance of the company.
• The Long-Term Incentive Plan is being utilized to reward key personnel.

Industry Context

This type of equity grant is a common practice in the biotech industry to incentivize and retain key executives.

Comparison to Industry Standards

• Equity grants are a standard component of executive compensation packages in the biotechnology sector.
• Companies like Amgen, Gilead, and Regeneron also use similar long-term incentive plans to align executive interests with shareholder value.
• The size of the grant is within the typical range for executive compensation at companies of similar size and stage of development.

Stakeholder Impact

• Shareholders may view this as a positive sign of management's commitment to the company's long-term success.
• Employees may see this as a positive sign of the company's commitment to rewarding key personnel.

Key Dates

Keywords

Fortress Biotech, restricted shares, executive compensation, insider transaction, Long-Term Incentive Plan, Michael S. Weiss, share ownership